Mylan's 3rd Circ. Doryx Loss A Hurdle To Product-Hop Suits
Mylan won't appeal an adverse Third Circuit ruling in an antitrust suit over acne treatment Doryx — and though the decision does not preclude product-hopping claims, it could make it harder...To view the full article, register now.
Already a subscriber? Click here to view full article